JPH01151462A - 腹膜灌流液 - Google Patents
腹膜灌流液Info
- Publication number
- JPH01151462A JPH01151462A JP62309675A JP30967587A JPH01151462A JP H01151462 A JPH01151462 A JP H01151462A JP 62309675 A JP62309675 A JP 62309675A JP 30967587 A JP30967587 A JP 30967587A JP H01151462 A JPH01151462 A JP H01151462A
- Authority
- JP
- Japan
- Prior art keywords
- peritoneal
- salt
- mucopolysaccharide
- perfusate
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012530 fluid Substances 0.000 title claims abstract description 9
- 230000010412 perfusion Effects 0.000 title abstract description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 11
- 239000008280 blood Substances 0.000 claims abstract description 8
- 210000004369 blood Anatomy 0.000 claims abstract description 8
- 239000008103 glucose Substances 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 230000003204 osmotic effect Effects 0.000 claims abstract description 6
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 3
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 3
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims abstract description 3
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 3
- 159000000003 magnesium salts Chemical class 0.000 claims abstract description 3
- 159000000000 sodium salts Chemical class 0.000 claims abstract description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract 3
- 229960002897 heparin Drugs 0.000 claims abstract 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims description 14
- 230000002262 irrigation Effects 0.000 claims description 7
- 238000003973 irrigation Methods 0.000 claims description 7
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 4
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 4
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 4
- 235000016709 nutrition Nutrition 0.000 claims description 4
- 229920002971 Heparan sulfate Polymers 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229920000288 Keratan sulfate Polymers 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims description 2
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 229940113601 irrigation solution Drugs 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 238000000502 dialysis Methods 0.000 abstract description 4
- 210000002966 serum Anatomy 0.000 abstract description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 2
- 230000006866 deterioration Effects 0.000 abstract 2
- 229920000669 heparin Polymers 0.000 abstract 2
- 102000011782 Keratins Human genes 0.000 abstract 1
- 108010076876 Keratins Proteins 0.000 abstract 1
- 229910021653 sulphate ion Inorganic materials 0.000 abstract 1
- 210000004303 peritoneum Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000007423 decrease Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000007774 longterm Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- -1 lactic acid alkali salt Chemical class 0.000 description 2
- 210000005033 mesothelial cell Anatomy 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000037313 granulation tissue formation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62309675A JPH01151462A (ja) | 1987-12-09 | 1987-12-09 | 腹膜灌流液 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62309675A JPH01151462A (ja) | 1987-12-09 | 1987-12-09 | 腹膜灌流液 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01151462A true JPH01151462A (ja) | 1989-06-14 |
| JPH0558604B2 JPH0558604B2 (enExample) | 1993-08-27 |
Family
ID=17995918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62309675A Granted JPH01151462A (ja) | 1987-12-09 | 1987-12-09 | 腹膜灌流液 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH01151462A (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998001141A1 (en) * | 1996-07-09 | 1998-01-15 | Bieffe Medital S.P.A. | Alternative osmotic agents and related solutions for peritoneal dialysis |
| WO2002069984A3 (de) * | 2001-03-02 | 2003-01-30 | Knoell Hans Forschung Ev | Verwendung von hyaluronsäure-uroniden zur behandlung von entzündlichen vorgängen |
| WO2005082384A1 (ja) * | 2004-02-27 | 2005-09-09 | Nihon Trim Co., Ltd. | 人工生理的塩類溶液およびその製造方法 |
| WO2009044765A1 (ja) | 2007-10-01 | 2009-04-09 | Seikagaku Corporation | 新規な低分子化コンドロイチン硫酸およびその用途 |
| WO2013174863A1 (en) | 2012-05-23 | 2013-11-28 | Altergon S.A. | Chondroitin for use in medicine |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
-
1987
- 1987-12-09 JP JP62309675A patent/JPH01151462A/ja active Granted
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998001141A1 (en) * | 1996-07-09 | 1998-01-15 | Bieffe Medital S.P.A. | Alternative osmotic agents and related solutions for peritoneal dialysis |
| WO2002069984A3 (de) * | 2001-03-02 | 2003-01-30 | Knoell Hans Forschung Ev | Verwendung von hyaluronsäure-uroniden zur behandlung von entzündlichen vorgängen |
| WO2005082384A1 (ja) * | 2004-02-27 | 2005-09-09 | Nihon Trim Co., Ltd. | 人工生理的塩類溶液およびその製造方法 |
| WO2009044765A1 (ja) | 2007-10-01 | 2009-04-09 | Seikagaku Corporation | 新規な低分子化コンドロイチン硫酸およびその用途 |
| US9149572B2 (en) | 2007-10-01 | 2015-10-06 | Seikagaku Corporation | Chondroitin sulfate having decreased molecular weight and use thereof |
| WO2013174863A1 (en) | 2012-05-23 | 2013-11-28 | Altergon S.A. | Chondroitin for use in medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0558604B2 (enExample) | 1993-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7122210B2 (en) | Bicarbonate-based solutions for dialysis therapies | |
| US7053059B2 (en) | Dialysis solutions with reduced levels of glucose degradation products | |
| US20040121982A1 (en) | Biocompatible dialysis fluids containing icodextrins | |
| JP5690040B2 (ja) | 重炭酸塩ベースの腹膜透析溶液 | |
| RU2005119309A (ru) | Способ перитонеального диализа | |
| JP2009051850A (ja) | Ｌ−カルノシンを含む腎不全の処置用の組成物 | |
| Gilmore et al. | Paracetamol-induced acute pancreatitis | |
| JPH01151462A (ja) | 腹膜灌流液 | |
| CN109364098B (zh) | 中性pH值腹膜透析液及其制备工艺 | |
| JP7520166B2 (ja) | 腹膜透析液、腹膜透析液セット、腹膜透析に使用される組成物および腹膜透析を行う方法 | |
| Gutch et al. | Periodic peritoneal dialysis in chronic renal insufficiency | |
| JPH1171273A (ja) | 腹膜透析液 | |
| JP7034933B2 (ja) | 透析濃縮液 | |
| JP2009522054A (ja) | ヘパリンを含む滅菌済腹膜透析溶液 | |
| Boen | Peritoneal dialysis: a clinical study of factors governing its effectiveness | |
| Ing et al. | Peritoneal dialysis using bicarbonate-buffered dialysate | |
| JP3643879B2 (ja) | 電解質輸液組成物 | |
| AU2008201009B2 (en) | Bicarbonate-based solutions for dialysis therapies | |
| McCaughan Jr et al. | Intermittent peritoneal lavage | |
| Mehbod et al. | Peritoneal Dialysis-1973 | |
| CN110075118A (zh) | 一种多功能外科手术冲洗液与其制备方法与应用 | |
| HK1088535B (en) | Biocompatible dialysis fluids containing icodextrins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |